Pyxis Oncology
PYXS
99 hedge funds and large institutions have $49.2M invested in Pyxis Oncology in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 18 closing their positions.
1,884% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $80K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
74% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 19
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
8% more funds holding
Funds holding: 92 → 99 (+7)
6.13% more ownership
Funds ownership: 46.93% → 53.06% (+6.1%)
52% less capital invested
Capital invested by funds: $102M → $49.2M (-$53.1M)
Top Buyers
| 1 |
Millennium Management
New York
|
+$3.1M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$2.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.21M |
| 4 |
BlackRock
New York
|
+$1.1M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$632K |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$15.4M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$4.13M |
| 3 |
SC
Stempoint Capital
New York
|
-$3.12M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$993K |
| 5 |
PA
Perceptive Advisors
New York
|
-$923K |
PYXS Hedge Fund Activity: Q4 2024 in Review
99 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q4 2024, worth a combined $49.2M — down 52% from $102M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PYXS positions and 18 closed out — a net gain of 7 holders — while 33 added to existing stakes and 19 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.1M. The largest seller was Deep Track Capital, exiting entirely with an estimated $15.4M sold.
- 99 institutional investors held Pyxis Oncology (PYXS) as of Q4 2024, up from 92 in Q3 2024.
- Funds reported $49.2M of Pyxis Oncology stock for Q4 2024, down 52% quarter-over-quarter.
- 25 funds opened new Pyxis Oncology positions in Q4 2024 and 18 closed out, a net change of +7 holders.
- The largest Pyxis Oncology buyer in Q4 2024 was Millennium Management, an estimated $3.1M added.
- The largest Pyxis Oncology seller in Q4 2024 was Deep Track Capital, an estimated $15.4M sold.
Based on aggregated 13F filings for Q4 2024.